

PRODUCT INFORMATION




GSK126

Item No. 15415

CAS Registry No.: 1346574-57-9
Formal Name: N-[(1,2-dihydro-4,6-dimethyl-2-oxo-3-pyridinyl)methyl]-3-methyl-1-[(1S)-1-methylpropyl]-6-[6-(1-piperazinyl)-3-pyridinyl]-1H-indole-4-carboxamide

MF: C₃₁H₃₈N₆O₂
FW: 526.7
Purity: ≥98%
UV/Vis.: λ_{max}: 235, 283 nm
Supplied as: A crystalline solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

GSK126 is supplied as a crystalline solid. A stock solution may be made by dissolving the GSK126 in the solvent of choice, which should be purged with an inert gas. GSK126 is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF). The solubility of GSK126 in these solvents is approximately 2, 15, and 25 mg/ml, respectively.

GSK126 is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, GSK126 should first be dissolved in DMF and then diluted with the aqueous buffer of choice. GSK126 has a solubility of approximately 0.5 mg/ml in a 1:1 solution of DMF:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

The histone H3 lysine 27 (H3K27) methyltransferase EZH2 plays an important role in regulating gene expression, and its aberrant activity is linked to the onset and progression of cancer.¹ GSK126 is a selective, S-adenosyl-methionine-competitive small molecule inhibitor of EZH2 methyltransferase activity ($K_i = 0.57$ nM; $IC_{50} = 9.9$ nM versus that of EZH1: $K_i = 89$ nM; $IC_{50} = 680$ nM).² It is more than 1,000-fold selective for EZH2 over other histone methyltransferases, including both SET-domain-containing and non-SET-domain-containing methyltransferases.² At concentrations of 7-252 nM, it has been shown to inhibit global H3K27 trimethylation levels and to reactivate silenced PRC2 target genes.² Furthermore, GSK126 can inhibit the proliferation of EZH2 mutant DLBCL cell lines ($IC_{50} = 28-61$ nM) as well as the growth of EZH2 mutant DLBCL xenografts in mice receiving a daily dose of 50 mg/kg.²

References

1. Simon, J.A. and Lange, C.A. Roles of the EZH2 histone methyltransferase in cancer epigenetics. *Mutat. Res.* **647**, 21-29 (2008).
2. McCabe, M.T., Ott, H.M., Ganji, G., et al. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. *Nature* **492(7427)**, 108-112 (2012).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 11/08/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD

ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM

WWW.CAYMANCHEM.COM